Home > Haematology > ASH 2021 > Haemophilia > rFVIIIFc establishes rapid tolerisation in haemophilia A with inhibitors

rFVIIIFc establishes rapid tolerisation in haemophilia A with inhibitors

Presented By
Dr Lynn Malec, Versiti Blood Research Institute, WI, USA
Conference
ASH 2021
Trial
verITI-8
Recombinant factor VIII Fc protein (rFVIIIFc) therapy realised immune tolerance in approximately 2 out of 3 patients with severe haemophilia A and high-titre inhibitors who underwent immune tolerance induction (ITI) therapy for the first time. In addition, the agent displayed a swift time to tolerisation and no relapses occurred. These results add to the optimisation of ITI therapy with the purpose of eradicating inhibitors in these patients [1]. The international immune tolerance study (NCT00212472) showed that 40% of patients with severe haemophilia with inhibitors in the intent-to-treat population achieved immune tolerance, in a median time of approximately 22 months after rFVIIIFc treatment initiation. However, recent retrospective evidence suggested a higher success rate and rapid tolerisation in patients who underwent ITI the...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on